Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 3:25 AM
Ignite Modification Date: 2025-12-25 @ 3:25 AM
NCT ID: NCT06849505
Eligibility Criteria: Inclusion Criteria: 1. The patient is first diagnosed with stroke through neurological examination, CT or MRI scan. 2. The vital signs are stable and there is a certain degree of upper limb motor dysfunction. 3. The age is between 20 and 80 years old. 4. The cognitive ability is not significantly affected and the patient can cooperate with various examinations and assessments, with a MMSE score ≥ 20 points. 5. There are no serious complications (such as pneumonia, heart failure, urinary tract infection or malnutrition). 6. There is no pathological condition that is a contraindication for TMS in the medical history (for example, patients with metal in the brain, such as aneurysm clips, patients with a cardiac pacemaker, pregnant women, or those with a history of epileptic seizures). 7. The patient or guardian agrees to sign the informed consent form. Exclusion Criteria: 1. Patients with severe heart, lung, liver, kidney diseases and malignant tumors; 2. Those with a history of aphasia, severe cognitive impairment or mental illness; 3. Patients who have had a history of epileptic seizures in the last month or are taking anti-epileptic drugs recently; 4. Those with severe visual or hearing impairments, unable to communicate normally; 5. People with metal implants, pacemakers, skull defects or other conditions that prevent them from undergoing TMS.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 20 Years
Maximum Age: 80 Years
Study: NCT06849505
Study Brief:
Protocol Section: NCT06849505